

**Experiment Number:** 10260 - 01

**Test Type:** Chronic PN

**Route:** DOSED FEED

**Species/Strain:** RATS/HSD

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

2-Hydroxy-4-methoxybenzophenone

**CAS Number:** 131-57-7

**Date Report Requested:** 09/22/2017

**Time Report Requested:** 09:11:24

**First Dose M/F:** 11/08/10 / 11/09/10

**Lab:** BAT

Final 2 Revision 1 - Core Only

**NTP Study Number:** C10260  
**Lock Date:** 07/22/2014  
**Cage Range:** ALL  
**Date Range:** ALL  
**Reasons For Removal:** 25021 TSAC  
**Removal Date Range:** ALL  
**Treatment Groups:** Include ALL  
**Study Gender:** Both  
**TDMSE Version:** 3.0.2.3\_002  
**PWG Approval Date:** 12/22/2016

25020 NATD

25019 MSAC

Experiment Number: 10260 - 01

Test Type: Chronic PN

Route: DOSED FEED

Species/Strain: RATS/HSD

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

2-Hydroxy-4-methoxybenzophenone

CAS Number: 131-57-7

Date Report Requested: 09/22/2017

Time Report Requested: 09:11:24

First Dose M/F: 11/08/10 / 11/09/10

Lab: BAT

Harlan Sprague Dawley RATS MALE	0 ppm Male	1000 ppm Male	3000 ppm Male	10000 ppm Male
---------------------------------	------------	---------------	---------------	----------------

**Disposition Summary**

<b>Animals Initially In Study</b>	<b>60</b>	<b>50</b>	<b>50</b>	<b>60</b>
<b>Early Deaths</b>				
<b>Moribund Sacrifice</b>	<b>12</b>	<b>15</b>	<b>18</b>	<b>10</b>
<b>Natural Death</b>	<b>8</b>	<b>6</b>	<b>8</b>	<b>7</b>
<b>Survivors</b>				
<b>Natural Death</b>	<b>1</b>			
<b>Terminal Sacrifice</b>	<b>29</b>	<b>29</b>	<b>24</b>	<b>33</b>
<b>Animals Examined Microscopically</b>	<b>50</b>	<b>50</b>	<b>50</b>	<b>50</b>

**ALIMENTARY SYSTEM**

Esophagus	(50)	(50)	(50)	(50)
Intestine Large, Cecum	(50)	(50)	(50)	(50)
Intestine Large, Colon	(50)	(50)	(50)	(50)
Parasite Metazoan	2 (4%)	6 (12%)	1 (2%)	2 (4%)
Intestine Large, Rectum	(50)	(50)	(50)	(50)
Parasite Metazoan	7 (14%)	5 (10%)	5 (10%)	6 (12%)
Arteriole, Necrosis, Fibrinoid				1 (2%)
Intestine Small, Duodenum	(50)	(50)	(50)	(50)
Artery, Inflammation, Chronic Active	1 (2%)			
Intestine Small, Ileum	(50)	(50)	(50)	(50)
Intestine Small, Jejunum	(50)	(50)	(50)	(50)
Liver	(50)	(50)	(50)	(50)
Basophilic Focus	1 (2%)	3 (6%)	1 (2%)	2 (4%)
Cholangiofibrosis				1 (2%)
Clear Cell Focus	29 (58%)	28 (56%)	27 (54%)	29 (58%)
Eosinophilic Focus	6 (12%)	8 (16%)	9 (18%)	8 (16%)
Extramedullary Hematopoiesis	3 (6%)		1 (2%)	2 (4%)
Fatty Change, Focal	1 (2%)			
Hepatodiaphragmatic Nodule	1 (2%)	3 (6%)		
Necrosis	1 (2%)			
Thrombus			1 (2%)	
Bile Duct, Cyst				1 (2%)
Bile Duct, Dilation	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10260 - 01

Test Type: Chronic PN

Route: DOSED FEED

Species/Strain: RATS/HSD

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

2-Hydroxy-4-methoxybenzophenone

CAS Number: 131-57-7

Date Report Requested: 09/22/2017

Time Report Requested: 09:11:24

First Dose M/F: 11/08/10 / 11/09/10

Lab: BAT

Harlan Sprague Dawley RATS MALE	0 ppm Male	1000 ppm Male	3000 ppm Male	10000 ppm Male
Bile Duct, Hyperplasia	20 (40%)	7 (14%)	12 (24%)	11 (22%)
Hepatocyte, Hypertrophy	2 (4%)			
Hepatocyte, Necrosis	1 (2%)	2 (4%)	2 (4%)	1 (2%)
Hepatocyte, Vacuolization Cytoplasmic	4 (8%)	6 (12%)	6 (12%)	7 (14%)
Portal, Fibrosis	1 (2%)			
Serosa, Fibrosis	1 (2%)			
Mesentery	(1)	(3)	(1)	(1)
Artery, Inflammation, Chronic Active	1 (100%)			
Fat, Necrosis		2 (67%)		
Oral Mucosa	(0)	(0)	(0)	(1)
Cyst				1 (100%)
Pancreas	(50)	(50)	(50)	(50)
Acinus, Atrophy	6 (12%)	2 (4%)		1 (2%)
Acinus, Atrophy, Focal		1 (2%)		
Acinus, Cyst		1 (2%)		
Acinus, Hyperplasia	14 (28%)	7 (14%)	14 (28%)	6 (12%)
Arteriole, Inflammation, Chronic Active	4 (8%)	15 (30%)	10 (20%)	11 (22%)
Arteriole, Necrosis, Fibrinoid	1 (2%)	3 (6%)	2 (4%)	
Artery, Inflammation, Chronic Active	15 (30%)	16 (32%)	20 (40%)	18 (36%)
Artery, Necrosis	3 (6%)			
Periductal, Cholangiofibrosis				1 (2%)
Salivary Glands	(50)	(50)	(50)	(50)
Stomach, Forestomach	(50)	(50)	(50)	(50)
Cyst		1 (2%)		
Fibrosis			2 (4%)	
Hemorrhage			1 (2%)	
Inflammation, Chronic Active	2 (4%)	1 (2%)	3 (6%)	2 (4%)
Mineral				1 (2%)
Arteriole, Necrosis, Fibrinoid				1 (2%)
Epithelium, Hyperplasia	2 (4%)		4 (8%)	2 (4%)
Stomach, Glandular	(50)	(50)	(50)	(50)
Mineral	2 (4%)	2 (4%)	2 (4%)	2 (4%)
Tongue	(0)	(0)	(0)	(1)
Epithelium, Hyperplasia				1 (100%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10260 - 01

Test Type: Chronic PN

Route: DOSED FEED

Species/Strain: RATS/HSD

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

2-Hydroxy-4-methoxybenzophenone

CAS Number: 131-57-7

Date Report Requested: 09/22/2017

Time Report Requested: 09:11:24

First Dose M/F: 11/08/10 / 11/09/10

Lab: BAT

---

Harlan Sprague Dawley RATS MALE	0 ppm Male	1000 ppm Male	3000 ppm Male	10000 ppm Male
---------------------------------	------------	---------------	---------------	----------------

---

CARDIOVASCULAR SYSTEM

Blood Vessel	(50)	(50)	(50)	(50)
Aorta, Hemorrhage		1 (2%)		
Aorta, Mineral		2 (4%)	1 (2%)	3 (6%)
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	37 (74%)	44 (88%)	42 (84%)	41 (82%)
Fibrosis		1 (2%)		
Infiltration Cellular, Mononuclear Cell	1 (2%)			
Inflammation, Chronic Active			1 (2%)	
Arteriole, Necrosis, Fibrinoid		1 (2%)		
Artery, Inflammation, Chronic Active	1 (2%)			
Atrium, Thrombus		1 (2%)	2 (4%)	
Endocardium, Proliferation				1 (2%)
Schwann Cell, Hyperplasia	2 (4%)			
Ventricle, Hypertrophy	1 (2%)			

---

ENDOCRINE SYSTEM

Adrenal Cortex	(50)	(50)	(50)	(50)
Angiectasis		1 (2%)		
Hyperplasia, Focal	18 (36%)	18 (36%)	19 (38%)	20 (40%)
Hyperplasia, Diffuse				1 (2%)
Hypertrophy, Focal	20 (40%)	23 (46%)	23 (46%)	27 (54%)
Metaplasia, Osseous		1 (2%)		
Necrosis	1 (2%)	1 (2%)	1 (2%)	
Thrombus			1 (2%)	1 (2%)
Vacuolization Cytoplasmic	5 (10%)	2 (4%)	3 (6%)	5 (10%)
Bilateral, Atrophy	1 (2%)			
Adrenal Medulla	(50)	(50)	(50)	(50)
Hyperplasia	27 (54%)	13 (26%)	15 (30%)	12 (24%)
Bilateral, Hyperplasia			1 (2%)	
Islets, Pancreatic	(50)	(50)	(50)	(50)
Fibrosis				1 (2%)
Parathyroid Gland	(49)	(47)	(45)	(48)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10260 - 01

Test Type: Chronic PN

Route: DOSED FEED

Species/Strain: RATS/HSD

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

2-Hydroxy-4-methoxybenzophenone

CAS Number: 131-57-7

Date Report Requested: 09/22/2017

Time Report Requested: 09:11:24

First Dose M/F: 11/08/10 / 11/09/10

Lab: BAT

Harlan Sprague Dawley RATS MALE	0 ppm Male	1000 ppm Male	3000 ppm Male	10000 ppm Male
Hyperplasia	27 (55%)	18 (38%)	15 (33%)	23 (48%)
Pituitary Gland	(50)	(50)	(50)	(50)
Pars Distalis, Hyperplasia	16 (32%)	17 (34%)	10 (20%)	16 (32%)
Pars Intermedia, Hyperplasia		3 (6%)	1 (2%)	
Thyroid Gland	(50)	(50)	(50)	(50)
C-cell, Hyperplasia	7 (14%)	9 (18%)	7 (14%)	4 (8%)
<b>GENERAL BODY SYSTEM</b>				
Peritoneum	(1)	(0)	(1)	(1)
<b>GENITAL SYSTEM</b>				
Epididymis	(50)	(50)	(50)	(50)
Hypospermia	7 (14%)	11 (22%)	9 (18%)	8 (16%)
Artery, Inflammation, Chronic Active	1 (2%)			
Penis	(2)	(0)	(0)	(1)
Edema	1 (50%)			
Inflammation, Chronic Active	1 (50%)			
Preputial Gland	(49)	(50)	(49)	(50)
Prostate	(50)	(50)	(50)	(49)
Inflammation, Suppurative	4 (8%)	2 (4%)	5 (10%)	4 (8%)
Epithelium, Hyperplasia				2 (4%)
Seminal Vesicle	(50)	(50)	(50)	(50)
Atrophy				1 (2%)
Inflammation, Suppurative	1 (2%)	2 (4%)	2 (4%)	2 (4%)
Testes	(50)	(50)	(50)	(50)
Edema	1 (2%)	1 (2%)		
Necrosis			1 (2%)	
Arteriole, Necrosis, Fibrinoid	16 (32%)	19 (38%)	16 (32%)	25 (50%)
Germinal Epithelium, Atrophy	13 (26%)	18 (36%)	12 (24%)	20 (40%)
Interstitial Cell, Hyperplasia	1 (2%)			5 (10%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10260 - 01

Test Type: Chronic PN

Route: DOSED FEED

Species/Strain: RATS/HSD

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

2-Hydroxy-4-methoxybenzophenone

CAS Number: 131-57-7

Date Report Requested: 09/22/2017

Time Report Requested: 09:11:24

First Dose M/F: 11/08/10 / 11/09/10

Lab: BAT

---

Harlan Sprague Dawley RATS MALE	0 ppm Male	1000 ppm Male	3000 ppm Male	10000 ppm Male
---------------------------------	------------	---------------	---------------	----------------

---

HEMATOPOIETIC SYSTEM

Bone Marrow	(50)	(50)	(50)	(50)
Hypercellularity	9 (18%)	12 (24%)	17 (34%)	10 (20%)
Lymph Node	(4)	(0)	(1)	(5)
Lumbar, Ectasia	2 (50%)			2 (40%)
Mediastinal, Congestion				1 (20%)
Mediastinal, Ectasia	1 (25%)			
Renal, Congestion				1 (20%)
Renal, Ectasia				2 (40%)
Lymph Node, Mandibular	(50)	(50)	(50)	(50)
Congestion	1 (2%)			
Inflammation, Suppurative				1 (2%)
Lymph Node, Mediastinal	(1)	(0)	(1)	(0)
Lymph Node, Mesenteric	(50)	(50)	(50)	(50)
Congestion	1 (2%)			
Spleen	(50)	(50)	(50)	(50)
Congestion		1 (2%)		
Extramedullary Hematopoiesis	21 (42%)	14 (28%)	14 (28%)	17 (34%)
Pigment	21 (42%)	24 (48%)	28 (56%)	27 (54%)
White Pulp, Atrophy	5 (10%)	5 (10%)	3 (6%)	9 (18%)
Thymus	(46)	(48)	(48)	(49)
Atrophy	17 (37%)	19 (40%)	21 (44%)	16 (33%)
Arteriole, Necrosis, Fibrinoid			1 (2%)	

---

INTEGUMENTARY SYSTEM

Mammary Gland	(49)	(50)	(50)	(50)
Skin	(50)	(50)	(50)	(50)
Cyst Epithelial Inclusion	1 (2%)	1 (2%)	4 (8%)	3 (6%)
Hyperkeratosis	1 (2%)			
Inflammation, Suppurative			3 (6%)	
Inflammation, Chronic		1 (2%)		1 (2%)
Inflammation, Chronic Active	3 (6%)	3 (6%)		
Metaplasia, Osseous				1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10260 - 01

Test Type: Chronic PN

Route: DOSED FEED

Species/Strain: RATS/HSD

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

2-Hydroxy-4-methoxybenzophenone

CAS Number: 131-57-7

Date Report Requested: 09/22/2017

Time Report Requested: 09:11:24

First Dose M/F: 11/08/10 / 11/09/10

Lab: BAT

Harlan Sprague Dawley RATS MALE	0 ppm Male	1000 ppm Male	3000 ppm Male	10000 ppm Male
Ulcer Epidermis, Hyperplasia	1 (2%)	1 (2%)		1 (2%)
<b>MUSCULOSKELETAL SYSTEM</b>				
Bone	(50)	(50)	(50)	(50)
Skeletal Muscle Degeneration	(2) 1 (50%)	(0)	(1)	(2)
<b>NERVOUS SYSTEM</b>				
Brain	(50)	(50)	(50)	(50)
Hemorrhage	1 (2%)			
Necrosis	1 (2%)			
Cerebrum, Edema		1 (2%)		
Cerebrum, Hemorrhage		1 (2%)		
Cerebrum, Neuron, Necrosis		1 (2%)		
Nerve Trigeminal	(0)	(0)	(1)	(0)
Peripheral Nerve	(2)	(1)	(1)	(0)
Axon, Degeneration	1 (50%)			
Sciatic, Degeneration	1 (50%)			
Trigeminal, Degeneration	1 (50%)			
Spinal Cord	(2)	(1)	(1)	(0)
Axon, Degeneration	2 (100%)		1 (100%)	
<b>RESPIRATORY SYSTEM</b>				
Lung	(50)	(50)	(50)	(50)
Hemorrhage	1 (2%)	2 (4%)	3 (6%)	1 (2%)
Inflammation, Suppurative		1 (2%)		
Inflammation, Granulomatous	1 (2%)	1 (2%)		
Inflammation, Histiocytic				1 (2%)
Necrosis		1 (2%)		
Proteinosis				1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10260 - 01

Test Type: Chronic PN

Route: DOSED FEED

Species/Strain: RATS/HSD

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

2-Hydroxy-4-methoxybenzophenone

CAS Number: 131-57-7

Date Report Requested: 09/22/2017

Time Report Requested: 09:11:24

First Dose M/F: 11/08/10 / 11/09/10

Lab: BAT

Harlan Sprague Dawley RATS MALE	0 ppm Male	1000 ppm Male	3000 ppm Male	10000 ppm Male
Alveolar Epithelium, Hyperplasia			1 (2%)	
Alveolus, Hemorrhage	1 (2%)			
Alveolus, Infiltration Cellular, Histiocyte	20 (40%)	15 (30%)	18 (36%)	17 (34%)
Alveolus, Infiltration Cellular, Mixed Cell	2 (4%)			
Interstitialium, Edema			1 (2%)	
Interstitialium, Fibrosis	1 (2%)		3 (6%)	1 (2%)
Interstitialium, Inflammation, Chronic				1 (2%)
Nose	(50)	(50)	(50)	(50)
Olfactory Epithelium, Accumulation, Hyaline Droplet	42 (84%)	47 (94%)	47 (94%)	44 (88%)
Trachea	(50)	(50)	(50)	(50)

## SPECIAL SENSES SYSTEM

Eye	(50)	(50)	(50)	(50)
Anterior Chamber, Inflammation, Suppurative		1 (2%)		
Bilateral, Cornea, Inflammation, Chronic Active	1 (2%)		1 (2%)	
Cornea, Inflammation, Chronic Active	2 (4%)			
Lens, Degeneration		1 (2%)		
Harderian Gland	(50)	(50)	(50)	(50)
Lacrimal Gland	(0)	(0)	(1)	(0)
Metaplasia, Harderian Gland			1 (100%)	
Zymbal's Gland	(0)	(1)	(0)	(0)

## URINARY SYSTEM

Kidney	(50)	(50)	(50)	(50)
Cyst	1 (2%)	2 (4%)	1 (2%)	3 (6%)
Hyperplasia		1 (2%)		
Nephropathy, Chronic Progressive	50 (100%)	50 (100%)	50 (100%)	50 (100%)
Capsule, Hemorrhage		1 (2%)		
Epithelium, Accumulation, Hyaline Droplet			1 (2%)	
Pelvis, Dilation				2 (4%)
Pelvis, Inflammation, Suppurative	1 (2%)	1 (2%)	2 (4%)	3 (6%)
Urinary Bladder	(50)	(50)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion



Experiment Number: 10260 - 01

Test Type: Chronic PN

Route: DOSED FEED

Species/Strain: RATS/HSD

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

2-Hydroxy-4-methoxybenzophenone

CAS Number: 131-57-7

Date Report Requested: 09/22/2017

Time Report Requested: 09:11:24

First Dose M/F: 11/08/10 / 11/09/10

Lab: BAT

---

Harlan Sprague Dawley RATS MALE	0 ppm Male	1000 ppm Male	3000 ppm Male	10000 ppm Male
Inflammation, Suppurative	1 (2%)	1 (2%)		3 (6%)

---

\*\*\* END OF MALE \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10260 - 01

Test Type: Chronic PN

Route: DOSED FEED

Species/Strain: RATS/HSD

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

2-Hydroxy-4-methoxybenzophenone

CAS Number: 131-57-7

Date Report Requested: 09/22/2017

Time Report Requested: 09:11:24

First Dose M/F: 11/08/10 / 11/09/10

Lab: BAT

Harlan Sprague Dawley RATS FEMALE	0 ppm Female	1000 ppm Female	3000 ppm Female	10000 ppm Female
-----------------------------------	--------------	-----------------	-----------------	------------------

**Disposition Summary**

<b>Animals Initially In Study</b>	<b>60</b>	<b>50</b>	<b>50</b>	<b>60</b>
<b>Early Deaths</b>				
<b>Moribund Sacrifice</b>	<b>15</b>	<b>13</b>	<b>10</b>	<b>16</b>
<b>Natural Death</b>	<b>5</b>	<b>4</b>	<b>6</b>	<b>8</b>
<b>Survivors</b>				
<b>Terminal Sacrifice</b>	<b>30</b>	<b>33</b>	<b>34</b>	<b>26</b>
<b>Animals Examined Microscopically</b>	<b>50</b>	<b>50</b>	<b>50</b>	<b>50</b>

## ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(50)
Intestine Large, Cecum	(50)	(50)	(50)	(50)
Intestine Large, Colon	(50)	(50)	(50)	(50)
Parasite Metazoan	2 (4%)	2 (4%)	4 (8%)	
Artery, Inflammation, Chronic Active			1 (2%)	1 (2%)
Intestine Large, Rectum	(50)	(50)	(50)	(50)
Parasite Metazoan	2 (4%)	3 (6%)	7 (14%)	10 (20%)
Arteriole, Necrosis, Fibrinoid				1 (2%)
Artery, Inflammation, Chronic Active			1 (2%)	
Intestine Small, Duodenum	(50)	(50)	(50)	(50)
Intestine Small, Ileum	(49)	(50)	(50)	(50)
Intestine Small, Jejunum	(50)	(50)	(50)	(50)
Artery, Inflammation, Chronic Active			1 (2%)	
Liver	(50)	(50)	(50)	(50)
Angiectasis	1 (2%)	3 (6%)		2 (4%)
Basophilic Focus	6 (12%)	11 (22%)	12 (24%)	4 (8%)
Clear Cell Focus	12 (24%)	9 (18%)	14 (28%)	7 (14%)
Congestion		1 (2%)		
Cyst			1 (2%)	
Eosinophilic Focus	15 (30%)	6 (12%)	16 (32%)	12 (24%)
Extramedullary Hematopoiesis	8 (16%)	7 (14%)	3 (6%)	7 (14%)
Mixed Cell Focus	1 (2%)			
Pigment			1 (2%)	
Bile Duct, Cyst	2 (4%)	2 (4%)	8 (16%)	2 (4%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10260 - 01

Test Type: Chronic PN

Route: DOSED FEED

Species/Strain: RATS/HSD

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

2-Hydroxy-4-methoxybenzophenone

CAS Number: 131-57-7

Date Report Requested: 09/22/2017

Time Report Requested: 09:11:24

First Dose M/F: 11/08/10 / 11/09/10

Lab: BAT

Harlan Sprague Dawley RATS FEMALE	0 ppm Female	1000 ppm Female	3000 ppm Female	10000 ppm Female
Bile Duct, Hyperplasia			2 (4%)	1 (2%)
Hepatocyte, Hypertrophy	5 (10%)	2 (4%)	2 (4%)	3 (6%)
Hepatocyte, Necrosis	2 (4%)	3 (6%)	2 (4%)	4 (8%)
Hepatocyte, Vacuolization Cytoplasmic		1 (2%)	1 (2%)	3 (6%)
Mesentery	(1)	(0)	(0)	(1)
Fat, Necrosis	1 (100%)			
Pancreas	(50)	(50)	(50)	(50)
Acinus, Atrophy	2 (4%)			
Acinus, Hyperplasia				1 (2%)
Arteriole, Inflammation, Chronic Active	1 (2%)	3 (6%)	3 (6%)	
Artery, Inflammation, Chronic Active	1 (2%)	3 (6%)	3 (6%)	2 (4%)
Salivary Glands	(49)	(50)	(50)	(50)
Stomach, Forestomach	(50)	(50)	(50)	(50)
Cyst, Squamous				1 (2%)
Ulcer			1 (2%)	
Epithelium, Hyperplasia			1 (2%)	2 (4%)
Stomach, Glandular	(50)	(50)	(50)	(50)

CARDIOVASCULAR SYSTEM

Blood Vessel	(50)	(50)	(50)	(50)
Heart	(49)	(50)	(50)	(50)
Cardiomyopathy		1 (2%)	3 (6%)	1 (2%)
Epicardium, Inflammation, Suppurative				1 (2%)

ENDOCRINE SYSTEM

Adrenal Cortex	(50)	(50)	(50)	(50)
Angiectasis		2 (4%)	1 (2%)	
Hyperplasia, Focal	9 (18%)	8 (16%)	12 (24%)	13 (26%)
Hypertrophy, Focal	24 (48%)	42 (84%)	39 (78%)	27 (54%)
Necrosis		1 (2%)	2 (4%)	
Thrombus				1 (2%)
Vacuolization Cytoplasmic		3 (6%)	3 (6%)	1 (2%)
Bilateral, Hyperplasia, Focal		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10260 - 01

Test Type: Chronic PN

Route: DOSED FEED

Species/Strain: RATS/HSD

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

2-Hydroxy-4-methoxybenzophenone

CAS Number: 131-57-7

Date Report Requested: 09/22/2017

Time Report Requested: 09:11:24

First Dose M/F: 11/08/10 / 11/09/10

Lab: BAT

Harlan Sprague Dawley RATS FEMALE	0 ppm Female	1000 ppm Female	3000 ppm Female	10000 ppm Female
Bilateral, Hypertrophy, Focal Adrenal Medulla Hyperplasia	1 (2%)	(50)	(50)	(50)
Islets, Pancreatic	12 (24%)	4 (8%)	11 (22%)	5 (10%)
Parathyroid Gland Hyperplasia	(50)	(50)	(50)	(50)
Pituitary Gland	(41)	(47)	(43)	(42)
Pars Distalis, Hyperplasia	(50)	1 (2%)	5 (12%)	3 (7%)
Pars Intermedia, Hyperplasia	(50)	(50)	(50)	(50)
Pars Nervosa, Cyst	13 (26%)	13 (26%)	9 (18%)	15 (30%)
Thyroid Gland	1 (2%)		2 (4%)	1 (2%)
C-cell, Hyperplasia	1 (2%)			
	(50)	(50)	(50)	(50)
	11 (22%)	11 (22%)	9 (18%)	9 (18%)

GENERAL BODY SYSTEM

Peritoneum	(0)	(0)	(0)	(1)
------------	-----	-----	-----	-----

GENITAL SYSTEM

Clitoral Gland Fibrosis	(48)	(50)	(50)	(48)
Ovary Cyst	1 (2%)	(50)	(50)	(50)
Inflammation, Suppurative	5 (10%)	2 (4%)	7 (14%)	9 (18%)
Bursa, Cyst		1 (2%)		
Periovarian Tissue, Inflammation, Suppurative		4 (8%)		2 (4%)
Uterus				1 (2%)
Adenomyosis	(50)	(50)	(50)	(50)
Dilation	3 (6%)	8 (16%)	3 (6%)	7 (14%)
Hemorrhage	2 (4%)	2 (4%)	1 (2%)	3 (6%)
Inflammation, Suppurative		2 (4%)		
Perforation	2 (4%)	1 (2%)		1 (2%)
Cervix, Stromal Hyperplasia		1 (2%)		1 (2%)
Endometrium, Atypical Hyperplasia	9 (18%)	14 (28%)	19 (38%)	14 (28%)
Endometrium, Hyperplasia, Cystic	35 (70%)	30 (60%)	28 (56%)	25 (50%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10260 - 01

Test Type: Chronic PN

Route: DOSED FEED

Species/Strain: RATS/HSD

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

2-Hydroxy-4-methoxybenzophenone

CAS Number: 131-57-7

Date Report Requested: 09/22/2017

Time Report Requested: 09:11:24

First Dose M/F: 11/08/10 / 11/09/10

Lab: BAT

---

Harlan Sprague Dawley RATS FEMALE	0 ppm Female	1000 ppm Female	3000 ppm Female	10000 ppm Female
Endometrium, Metaplasia, Squamous	36 (72%)	35 (70%)	25 (50%)	32 (64%)
Vagina	(50)	(50)	(50)	(50)
Mucification	9 (18%)	2 (4%)	7 (14%)	6 (12%)
Parasite Metazoan		1 (2%)		

---

HEMATOPOIETIC SYSTEM

Bone Marrow	(50)	(50)	(50)	(50)
Hypercellularity	34 (68%)	26 (52%)	25 (50%)	32 (64%)
Lymph Node	(0)	(1)	(2)	(1)
Mediastinal, Congestion			2 (100%)	
Lymph Node, Mandibular	(49)	(50)	(49)	(50)
Lymph Node, Mesenteric	(49)	(50)	(50)	(50)
Hemorrhage		1 (2%)		
Spleen	(50)	(50)	(50)	(50)
Extramedullary Hematopoiesis	33 (66%)	26 (52%)	30 (60%)	24 (48%)
Hemorrhage		1 (2%)		
Necrosis				1 (2%)
Pigment	31 (62%)	33 (66%)	37 (74%)	34 (68%)
White Pulp, Atrophy	2 (4%)	2 (4%)		4 (8%)
Thymus	(49)	(50)	(47)	(49)
Atrophy	17 (35%)	16 (32%)	12 (26%)	22 (45%)
Inflammation, Suppurative				1 (2%)

---

INTEGUMENTARY SYSTEM

Mammary Gland	(50)	(50)	(50)	(49)
Galactocele	3 (6%)	5 (10%)	3 (6%)	1 (2%)
Hyperplasia	1 (2%)	2 (4%)	3 (6%)	1 (2%)
Skin	(50)	(50)	(50)	(50)
Erosion			1 (2%)	

---

MUSCULOSKELETAL SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10260 - 01

Test Type: Chronic PN

Route: DOSED FEED

Species/Strain: RATS/HSD

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

2-Hydroxy-4-methoxybenzophenone

CAS Number: 131-57-7

Date Report Requested: 09/22/2017

Time Report Requested: 09:11:24

First Dose M/F: 11/08/10 / 11/09/10

Lab: BAT

Harlan Sprague Dawley RATS FEMALE	0 ppm Female	1000 ppm Female	3000 ppm Female	10000 ppm Female
Bone	(50)	(50)	(50)	(50)
<b>NERVOUS SYSTEM</b>				
Brain	(50)	(50)	(50)	(50)
Gliosis			1 (2%)	
Hemorrhage				1 (2%)
Hydrocephalus	1 (2%)			
Inflammation, Histiocytic			1 (2%)	
Necrosis			1 (2%)	
Cerebrum, Gliosis				1 (2%)
Cerebrum, Necrosis				1 (2%)
Meninges, Hyperplasia, Granular Cell	1 (2%)			
<b>RESPIRATORY SYSTEM</b>				
Lung	(49)	(50)	(50)	(50)
Hemorrhage		1 (2%)		3 (6%)
Hyperplasia, Squamous		1 (2%)		
Pigment		1 (2%)		
Alveolus, Cytoplasmic Alteration		1 (2%)		
Alveolus, Hyperplasia, Cystic		1 (2%)		
Alveolus, Infiltration Cellular, Histiocyte	38 (78%)	38 (76%)	45 (90%)	40 (80%)
Interstitial, Fibrosis		1 (2%)		
Nose	(50)	(50)	(50)	(50)
Olfactory Epithelium, Accumulation, Hyaline Droplet	49 (98%)	48 (96%)	50 (100%)	47 (94%)
Trachea	(50)	(50)	(50)	(50)
<b>SPECIAL SENSES SYSTEM</b>				
Eye	(50)	(50)	(50)	(50)
Lens, Degeneration				1 (2%)
Retina, Degeneration				1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 10260 - 01

Test Type: Chronic PN

Route: DOSED FEED

Species/Strain: RATS/HSD

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

2-Hydroxy-4-methoxybenzophenone

CAS Number: 131-57-7

Date Report Requested: 09/22/2017

Time Report Requested: 09:11:24

First Dose M/F: 11/08/10 / 11/09/10

Lab: BAT

---

Harlan Sprague Dawley RATS FEMALE	0 ppm Female	1000 ppm Female	3000 ppm Female	10000 ppm Female
Harderian Gland	(50)	(50)	(50)	(50)
Zymbal's Gland	(0)	(0)	(0)	(1)

---

URINARY SYSTEM

Kidney	(50)	(50)	(50)	(50)
Atrophy	1 (2%)			
Infarct		1 (2%)		
Mineral			2 (4%)	
Nephropathy, Chronic Progressive	44 (88%)	46 (92%)	46 (92%)	45 (90%)
Papilla, Degeneration				1 (2%)
Pelvis, Dilation	1 (2%)			
Pelvis, Inflammation, Suppurative		1 (2%)		1 (2%)
Urinary Bladder	(49)	(50)	(50)	(50)
Inflammation, Suppurative		1 (2%)		

---

\*\*\* END OF REPORT \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion